Cardiol Therapeutics (CRDL) Non Operating Investment Income (2022 - 2026)

Cardiol Therapeutics' Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• Quarterly Non Operating Investment Income changed N/A year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383679.7 (changed N/A YoY) and the FY2025 annual result came in at $682481.9, up 300.29% from the prior year.
• Non Operating Investment Income was -$1.1 million for Q1 2026 at Cardiol Therapeutics, down from $2610.7 in the prior quarter.
• Across five years, Non Operating Investment Income topped out at $1.7 million in Q1 2022 and bottomed at -$1.3 million in Q1 2024.
• A 4-year average of $305740.2 and a median of $419901.6 in 2023 frame the typical range for Non Operating Investment Income.
• Peak annual rise in Non Operating Investment Income reached 238.21% in 2024, while the deepest fall reached 2549.36% in 2024.
• Cardiol Therapeutics' Non Operating Investment Income stood at $1.1 million in 2022, then slumped by 62.59% to $419901.6 in 2023, then plunged by 99.38% to $2610.7 in 2024, then plunged by 42821.61% to -$1.1 million in 2026.
• Business Quant data shows CRDL's Non Operating Investment Income at -$1.1 million in Q1 2026, $2610.7 in Q4 2024, and $991150.5 in Q3 2024.